TransMedics Group, Inc.

NasdaqGM TMDX

TransMedics Group, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 5.23

TransMedics Group, Inc. Price to Sales Ratio (P/S) is 5.23 on January 14, 2025, a -51.50% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

TransMedics Group, Inc. 52-week high Price to Sales Ratio (P/S) is 16.86 on June 28, 2024, which is 222.20% above the current Price to Sales Ratio (P/S).
TransMedics Group, Inc. 52-week low Price to Sales Ratio (P/S) is 4.96 on December 30, 2024, which is -5.21% below the current Price to Sales Ratio (P/S).
TransMedics Group, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 11.55.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

NasdaqGM: TMDX

TransMedics Group, Inc.

CEO	Dr. Waleed H. Hassanein M.D.
IPO Date	May 2, 2019
Location	United States
Headquarters	200 Minuteman Road
Employees	584
Sector	Health Care
Industries Biotechnology Medical Instruments Pharmaceuticals

Description

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

Key trends

Past 5 years